Table 5. Guidelines for postexposure immunoprophylaxis of unvaccinated persons who have an identifiable exposure to blood or body fluids that contain blood
This web page is archived for historical purposes and is no longer being updated. Newer content is available at www.cdc.gov/std/treatment
|Exposure to an HBsAg*-positive source||Percutaneous (e.g., bite or needlestick) or mucosal exposure to HBsAg-positive blood or body fluids that contain blood||Administer hepatitis B vaccine & HBIG†|
|Sexual or needle-sharing contact of an HBsAg-positive person||Administer hepatitis B vaccine & HBIG†|
|Victim of sexual assault/abuse by a perpetrator who is HBsAg positive||Administer hepatitis B vaccine & HBIG†|
|Exposure to a source with unknown HBsAg status||Victim of sexual assault/abuse by a perpetrator with unknown HBsAg status||Administer hepatitis B vaccine†|
|Percutaneous (e.g., bite or needlestick) or mucosal exposure to blood or body fluids that contain blood from a source with unknown HBsAg status||Administer hepatitis B vaccine†|
* Hepatitis B surface antigen.
† Immunoprophylaxis should be administered as soon as possible, preferably ≤24 hours. Studies are limited on the maximum interval after exposure during which postexposure prophylaxis is effective, but the interval is unlikely to exceed 7 days for percutaneous exposures and 14 days for sexual exposures. The complete, 3-dose hepatitis B vaccine series should be administered.
- Page last reviewed: January 28, 2011 (archived document)
- Content source: